PMGC Holdings reported that NorthStrive Biosciences' Phase III AI-driven program validated four small-molecule candidates that increase ANT1 expression in human skeletal muscle cells.
Key Highlights:
- Phase III with Yuva Biosciences' MitoNova™ AI biologically validated four AI-selected compounds (C1–C4) that raised ANT1.
- Top dose-dependent increases: C2 up to +50%, C4 up to +48%, C1 up to +46%; C3 showed +29% at highest dose.
- Results support advancing the four candidates into confirmatory testing in a more mature, energy-demanding muscle model.
- Study used primary human skeletal muscle cells and focused on ANT1, a mitochondrial protein tied to muscle energy metabolism and preservation.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.